Home›Oncology› Hugo RAS system shows no significant difference from other platforms in partial nephrectomy for renal cell carcinoma
Hugo RAS system shows no significant difference from other platforms in partial nephrectomy for renal cell carcinomaHugo RAS system shows similar results to other kidney surgeries
Journal of robotic surgeryPublished October 12, 2026Study authors: Lv ZongYing, Zhang Ren, Wei Wei, Cai QinFeng, Liu Man, Wu JiaLi, Liu Qi, Li ChaoMin, Xiong JianGuoPubMed ↗DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that Hugo RAS shows no significant difference from other platforms in partial nephrectomy for renal cell carcinoma.
This meta-analysis evaluates the Hugo RAS system as a surgical platform for partial nephrectomy in patients with renal cell carcinoma. The analysis compared the Hugo system against the da Vinci platform and traditional laparoscopy across several clinical metrics, including surgical duration, intraoperative blood loss, and postoperative outcomes.
The meta-analysis found no statistically significant differences across all measured outcomes. Specifically, surgery duration (MD = 2.81 min, 95% CI [-37.42, 43.03], p = 0.89), hospitalization duration (MD = -0.23 days, 95% CI [-1.59, 1.13], p = 0.74), and intraoperative blood loss (MD = 18.5 ml, 95% CI [-53.61, 90.6], p = 0.62) showed no significant variation. Furthermore, results for serum creatinine (MD = -0.05 mg/dl, p = 0.44), positive surgical margin incidence (OR = 0.59, p = 0.35), and trifecta attainment (OR = 1.11, p = 0.74) were not statistically significant.
Safety outcomes, including minor-to-moderate adverse events (OR = 0.98, p = 0.97) and major adverse events (OR = 0.74, p = 0.78), showed no significant differences between platforms. The authors note that evidence is preliminary because the included studies were mostly single-center and small-sample. Large multi-site randomized clinical trials are required to confirm these findings. Currently, the Hugo RAS system appears to be a reasonable surgical alternative to other minimally invasive procedures for partial nephrectomy.
How this fits prior evidence
This meta-analysis addresses a gap in comparing newer robotic platforms for renal cell carcinoma surgery. While previous evidence noted that sutureless renorrhaphy is noninferior to conventional renorrhaphy for trifecta achievement in robot-assisted partial nephrectomy, this study specifically evaluates the Hugo RAS platform. The findings suggest the Hugo system is a comparable alternative to existing platforms, though the evidence is preliminary due to small, single-center study designs.
When patients face kidney cancer, the choice of surgical technology is a major decision. A recent review of 383 patients undergoing partial nephrectomy for renal cell carcinoma looked at how the Hugo RAS system compares to the da Vinci platform and traditional laparoscopy. The goal was to see if this specific robotic system changed outcomes like surgery time, blood loss, or recovery speed.
The data showed that the Hugo RAS system performed similarly to other methods. There were no significant differences in how long the surgery took, the amount of blood lost, or the length of time patients stayed in the hospital. Additionally, the rates of major and minor complications were comparable across the different surgical platforms.
While the results suggest that the Hugo system is a reasonable alternative for kidney surgery, the evidence is still early. Because the data came from small, single-center studies, larger multi-site trials are still needed to confirm these findings. For now, the technology appears to offer a comparable experience to existing minimally invasive options.
What this means for you:
The Hugo RAS system shows similar safety and recovery results to other common kidney surgery methods.
Common questions
Is the Hugo RAS system safe for kidney cancer surgery?
The data suggests the Hugo RAS system is a reasonable alternative to other minimally invasive methods. The study found no statistically significant difference in the rate of minor to moderate complications or major complications when compared to other platforms.
Does the Hugo RAS system change recovery time or blood loss?
No significant differences were found regarding recovery. The study showed no significant variation in the duration of hospitalization, the amount of blood lost during surgery, or the level of serum creatinine following the procedure.
How does it compare to the da Vinci platform?
The study found no statistically significant differences between the Hugo RAS system and the da Vinci platform or traditional laparoscopy in terms of surgery duration, blood loss, or the rate of successful outcomes.
Renal cell carcinoma (RCC) is a common urologic malignancy, and for localized T1 tumors, nephron-sparing surgery is now the standard of care. Laparoscopic and image-guided techniques have advanced as robotic platform procedures offer greater operator dexterity and procedural control. The da Vinci platform has dominated robot-assisted partial nephrectomy, but high costs and closed architecture limit broader use. The Hugo™ RAS system, featuring a modular design, has emerged as a promising alternative, with early studies showing feasibility and safety. However, current evidence remains preliminary, mostly single-center and small-sample. This meta-analysis aggregates data and conducts subgroup analyses to compare Hugo™ RAS with other techniques, aiming to provide more precise effect estimates and guide surgical platform selection. The four main databases (PubMed, EMBASE, Web of Science, and Cochrane Library) were thoroughly searched to identify eligible clinical studies. The selected research involved comparative evaluations of surgical metrics of partial nephrectomy performed with Hugo™ RAS vs. the da Vinci system and traditional laparoscopy. This systematic synthesis included four observational cohort studies with a total of 383 subjects. Combined metric evaluations indicated that Hugo™ RAS demonstrated no statistically significant variation relative to alternative minimally invasive approaches regarding surgery duration (MD = 2.81 min, 95% CI [- 37.42, 43.03], p = 0.89), duration of hospitalization (MD = - 0.23 days, 95% CI [- 1.59, 1.13], p = 0.74), intraoperative blood loss (MD = 18.5 ml, 95% CI [- 53.61, 90.6], p = 0.62), serum creatinine following surgery (MD = - 0.05 mg/dl, 95% CI [- 0.18, 0.08], p = 0.44), positive surgical margin incidence (OR = 0.59, 95% CI [0.19, 1.80], p = 0.35), minor-to-moderate postoperative adverse event frequency (OR = 0.98, 95% CI [0.45, 2.17], p = 0.97), major postoperative adverse event frequency (OR = 0.74, 95% CI [0.09, 6.17], p = 0.78), overall postoperative adverse event rate (OR = 1.05, 95% CI [0.39, 2.87], p = 0.92), or successful trifecta attainment (OR = 1.11, 95% CI [0.60, 2.07], p = 0.74). This meta-analysis provided some preliminary evidence: Hugo™ RAS did not demonstrate significant differences compared to other minimally invasive surgical procedures in terms of procedure time, hospital stay, intraoperative blood loss, postoperative renal function, rate of positive margins, postoperative morbidity, and composite success results. Overall, Hugo™ RAS seems to be a reasonable surgical alternative. However, large multi-site randomized clinical trials are still needed to substantiate this finding.
